Philippe Outrebon’s Post

SE-9 is a novel dual-targeting SOS1/EGFR inhibitor that represents a promising treatment strategy for prostate cancer. Multitarget medications represent an appealing therapy against the disease with multifactorial abnormalities─cancer. Therefore, simultaneously targeting son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR), two aberrantly expressed proteins crucial for the oncogenesis and progression of prostate cancer, may achieve active antitumor effects. Chemenu has been working to develop more compounds for drug discovery. Here comes the building blocks we can provide: https://lnkd.in/gs3rA47M #SE-9 #SOS1/EGFR #dual-targetinginhibitor #prostatecancer #buildingblocks

We’re thrilled to announce that #preclinicaldata highlighting the differentiating properties of MYTX-011, our investigational cMET-targeting #ADC, has been published in the latest issue of Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research. Learn more: https://lnkd.in/ezrt85xm.   Discover how MYTX-011 has the potential to benefit a broader set of patients by offering increased on-target potency, enhanced tolerability, a longer half-life and higher efficacy when compared to other ADCs. Read the full article here: https://lnkd.in/eM44ZFH4.  

Engineering an exosome-based drug delivery system for synergistic cancer therapy: in this work, Xin Hua, Songqin Liu at Southeast University developed an exosome-based drug delivery system that combines miRNA-mediated autophagy inhibition with 7-coumarin chemotherapy for enhanced ovarian cancer treatment https://lnkd.in/ejEGR2tv They found that the engineered exosome-based drug delivery system enhanced drug uptake and improved targeting specificity towards cancer cells. An article co-authored by Yu Liu, Xi Liu, Qian Zhu, Sisi Zhou and Quan Li #extracellularvesicles #exosomes #bioengineering #ovariancancer #drugdelivery #Vesiculab

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer https://bit.ly/3Bbwy5o #PancreaticCancer #OvarianCancer #BreastCancer #ColorectalCancer #LongCOVID #MECFS

🔬 Insights from ASCO 2024! Prof els Van Nieuwenhuysen from University Hospitals Leuven presents the ongoing trial on ubamatamab for recurrent ovarian and endometrial cancer. The study explores dose escalation, early efficacy signals, and strategies to mitigate cytokine release syndrome. Learn more about the potential of this bispecific antibody therapy. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #GynaecologicalCancer #OncologyInnovation #OvarianCancer #EndometrialCancer

🎗️ 📢 Prostate Cancer Awareness Month📢🎗️ September 1st marked the start of Prostate Cancer Awareness Month. This month serves as a crucial reminder of the importance of understanding Prostate Cancer. Becoming aware of the risks and symptoms of Prostate Cancer could lead to earlier diagnosis and more effective treatments. Throughout this month, Verity Pharmaceuticals will be sharing valuable insights, facts, and resources on Prostate Cancer. Stay tuned to our page so you don’t miss a post! #MensHealth #ProstateCancerAwareness #PCAM #ProstateCancer

Label expansion is always a better option; it opens up opportunities for other drugs as well. CDKi moving towards an early stage is opening an opportunity for a CDKi progressor or intolerant patient pool for later lines. Ribociclib is the only CDK4/6 inhibitor with a statistically significant OS advantage in the first-line setting. We must also discuss the adverse effect profiles of CDKi and the required monitoring and consider patient comorbidities.

Halda Therapeutics secures $126 million in Series B extension to advance RIPTAC cancer therapies into clinical trials for metastatic prostate and breast cancer, with the first trial set for 2025. RIPTAC (Regulated Induced Proximity Targeting Chimeras) therapeutics are oral, precision molecules designed to selectively kill cancer cells by targeting two proteins, overcoming drug resistance in major solid tumors. More on funding and mechanism of action in the comment section. #cancer #drugresistance

Exploring Antibody-Based Cancer Therapies 🔬 Dive into our white paper on: - Monoclonal Antibodies - Antibody-Drug Conjugates - Multispecific Antibodies 🎯 Learn about the mechanisms, developments, and common challenges, like identifying suitable target antigens. 💡 At Revvity, our immunoassays help characterize these therapies, supporting the discovery and development of effective treatments. 📖 Interested? Click below to read/download. #CancerResearch #AntibodyTherapeutics #Revvity

Molecules of the Month – September 2024 | https://lnkd.in/gjAbvjaF September’s Molecules of the Month include Genentech's HPK1 inhibitor for cancer immunotherapy and Novo Nordisk's CB1 receptor inverse agonist for metabolic disorders. We also feature TAK-861, Takeda's highly selective OX2R agonist, which has entered a pivotal Ph. III trial, and Boehringer Ingelheim's pan-KRAS heterobifunctional degrader. Read the full article to find out what compounds made our September 2024 Molecules of the Month list, and check out recent articles for each. Full Article: https://lnkd.in/gjAbvjaF